HPLC Method for Quantification of Caffeine and Its Three Major Metabolites in Human Plasma Using Fetal Bovine Serum Matrix to Evaluate Prenatal Drug Exposure

Journal of Analytical Methods in Chemistry

Volumn 2018, Issue , 2018, Pages

  Lopez Sanchez, Rosa Del Carmen ^a   Lara Diaz, Victor Javier ^a   Aranda Gutierrez, Alejandro ^a   Martinez Cardona, Jorge A ^a   Hernandez, Jose A ^a  

^a ESCUELA DE MEDICINA Y CIENCIAS DE LA SALUD   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; FETUS; HUMAN; LIMIT OF QUANTITATION; NEWBORN; NEWBORN APNEA; NONHUMAN; PLASMA; PRENATAL DRUG EXPOSURE; QUALITY CONTROL; SERUM; SOLID PHASE EXTRACTION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 85052709006     PISSN: 20908865     EISSN: 20908873     Source Type: Journal    
DOI: 10.1155/2018/2085059     Document Type: Article

References (34)

1. C. J. Reissig, E. C. Strain, and R. R. Griffiths, "Caffeinated energy drinks-A growing problem," Drug and Alcohol Dependence, vol. 99, no. 1-3, pp. 1-10, 2009.
2. R. D. Goldman, "Caffeinated energy drinks in children," Canadian Family Physician, vol. 59, no. 9, pp. 947-948, 2013.
3. B. B. Fredholm, J. F. Chen, R. A. Cunha, P. Svenningsson, and J. M. Vaugeois, "Adenosine and brain function," International Review of Neurobiology, vol. 63, pp. 191-270, 2005.
4. J.-F. Chen, H. K. Eltzschig, and B. B. Fredholm, "Adenosine receptors as drug targets-what are the challenges?," Nature Reviews Drug Discovery, vol. 12, no. 4, pp. 265-286, 2013.
5. J. Zhao, F. Gonzalez, and D. Mu, "Apnea of prematurity: from cause to treatment," European Journal of Pediatrics, vol. 170, no. 9, pp. 1097-1105, 2011.
6. G. M. Pacifici, "Clinical pharmacology of theophylline in preterm infants: effects, metabolism and pharmacokinetics," Current Pediatric Reviews, vol. 10, no. 4, pp. 297-303, 2014.
7. A. Aldridge, J. V Aranda, and A. H. Neims, "Caffeine metabolism in the newborn," Clinical Pharmacology and Cerapeutics, vol. 25, no. 4, pp. 447-453, 1979.
8. G. Natarajan, M. Lulic-Botica, and J. V. Aranda, "Pharmacology review clinical pharmacology of caffeine in the newborn," Neoreviews, vol. 8, no. 5, pp. e214-e221, 2007.
9. J. E. Scanlon, K. C. Chin, M. E. Morgan, G. M. Durbin, K. A. Hale, and S. S. Brown, "Caffeine or theophylline for neonatal apnoea?," Archives of Disease in Childhood, vol. 67, no. 4, pp. 425-428, 1992.
10. C. Cazeneuve, G. Pons, E. Rey et al., "Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults," British Journal of Clinical Pharmacology, vol. 37, no. 5, pp. 405-412, 1994.
11. G. Pons, O. Carrier, M. O. Richard et al., "Developmental changes of caffeine elimination in infancy," Developmental Pharmacology and Cerapeutics, vol. 11, no. 5, pp. 258-264, 1988.
12. N. Y. Jordan, J. Y. Mimpen, W. J. M. van den Bogaard, F. M. Flesch, M. H. M. van de Meent, and J. S. Torano, "Analysis of caffeine and paraxanthine in human saliva with ultra-high-performance liquid chromatography for CYP1A2 phenotyping," Journal of Chromatography B, vol. 995-996, pp. 70-73, 2015.
13. B. Schmidt, R. Roberts, and P. Davis, "Long-term effects of caffeine therapy for apnea of prematurity," New England Journal of Medicine, vol. 357, no. 19, pp. 1893-1902, 2007.
14. B. G. Charles, S. R. Townsend, P. A. Steer, V. J. Flenady, P. H. Gray, and A. Shearman, "Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring," Cerapeutic Drug Monitoring, vol. 30, no. 6, pp. 709-716, 2008.
15. P. H. Gray, V. J. Flenady, B. G. Charles, and P. A. Steer, "Caffeine citrate for very preterm infants: effects on development, temperament and behaviour," Journal of Paediatrics and Child Health, vol. 47, no. 4, pp. 167-172, 2011.
16. J. J. Carvalho, M. G. Weller, U. Panne, and R. J. Schneider, "A highly sensitive caffeine immunoassay based on a monoclonal antibody," Analytical and Bioanalytical Chemistry, vol. 396, no. 7, pp. 2617-2628, 2010.
17. H. Li, C. Zhang, J. Wang, Y. Jiang, J. P. Fawcett, and J. Gu, "Simultaneous quantitation of paracetamol, caffeine, pseudoephedrine, chlorpheniramine and cloperastine in human plasma by liquid chromatography-tandem mass spectrometry," Journal of Pharmaceutical and Biomedical Analysis, vol. 51, no. 3, pp. 716-722, 2010.
18. A. S. Ptolemy, E. Tzioumis, A. Thomke, S. Rifai, and M. Kellogg, "Quantification of theobromine and caffeine in saliva, plasma and urine via liquid chromatography-tandem mass spectrometry: a single analytical protocol applicable to cocoa intervention studies," Journal of Chromatography B, vol. 878, no. 3-4, pp. 409-416, 2010.
19. S. N. Alvi and M. M. Hammami, "Validated HPLC method for determination of caffeine level in human plasma using synthetic plasma: application to bioavailability studies," Journal of Chromatographic Science, vol. 49, no. 4, pp. 292-296, 2011.
20. V. Perera, A. S. Gross, and A. J. McLachlan, "Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma," Biomedical Chromatography, vol. 24, no. 10, pp. 1136-1144, 2010.
21. M. A. Klebanoff and S. A. Keim, "Maternal serum paraxanthine during pregnancy and offspring body mass index at ages 4 and 7 years," Epidemiology, vol. 26, no. 2, pp. 185-191, 2015.
22. D.-K. Li, J. R. Ferber, and R. Odouli, "Maternal caffeine intake during pregnancy and risk of obesity in offspring: a prospective cohort study," International Journal of Obesity, vol. 39, no. 4, pp. 658-664, 2015.
23. F. P. Vitti, N. Adati, H. Bettiol et al., "Association of caffeine consumption with preterm birth and low birthweight in RibeirÃo Preto, SÃo Paulo, Brazil," Archives of Disease in Childhood, vol. 99, no. 2, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil, pp. A223.3-A224, 2014.
24. COFEPRIS, NOM-177-SSA1-2013, 2013.
25. FDA, Guidance for Industry: Bioanalytical Method Validation, U.S. Department of Health and Human Services, Washington, DC, USA, 2013.
26. G. Marcelín-Jiménez, J. Hernández, A. P. Ángeles et al., "Bioequivalence evaluation of two brands of ketoconazole tablets (Onofin-K® and Nizoral®) in a healthy female Mexican population," Biopharmaceutics & Drug Disposition, vol. 25, no. 5, pp. 203-209, 2004.
27. P. N. Patil, "Caffeine in various samples and their analysis with HPLC-a review," International Journal of Pharmaceutical Sciences Review and Research, vol. 16, no. 2, pp. 76-83, 2012.
28. B. Weldegebreal, M. Redi-Abshiro, and B. S. Chandravanshi, "Development of new analytical methods for the determination of caffeine content in aqueous solution of green coffee beans," Chemistry Central Journal, vol. 11, no. 1, 2017.
29. M. Makarska-Bialokoz, "Spectroscopic evidence of xanthine compounds fluorescence quenching effect on water-soluble porphyrins," Journal of Molecular Structure, vol. 1081, pp. 224-232, 2015.
30. W. Xu, T.-H. Kim, D. Zhai et al., "Make caffeine visible: a fluorescent caffeine "traffic light" detector," Scientific Reports, vol. 3, no. 1, 2013.
31. H. Kanazawa, R. Atsumi, Y. Matsushima, and J. Kizu, "Determination of theophylline and its metabolites in biological samples by liquid chromatography-mass spectrometry," Journal of Chromatography A, vol. 870, no. 1-2, pp. 87-96, 2000.
32. L. M. Grosso, E. Triche, N. L. Benowitz, and M. B. Bracken, "Prenatal caffeine assessment: fetal and maternal biomarkers or self-reported intake?," Annals of Epidemiology, vol. 18, no. 3, pp. 172-178, 2008.
33. S. K. Griffiths and J. P. Campbell, "Placental structure, function and drug transfer," Continuing Education in Anaesthesia Critical Care & Pain, vol. 15, no. 2, pp. 84-89, 2015.
34. K. C. Worley, S. W. Roberts, and R. E. Bawdon, "The metabolism and transplacental transfer of oseltamivir in the ex vivo human model," Infectious Diseases in Obstetrics and Gynecology, vol. 2008, Article ID 927574, 5 pages, 2008.